VNDA
Vanda Pharmaceuticals Inc.
Next earnings Jul 29, 2026 · consensus $-0.60 EPS, $63.2M rev
Last earnings +0.7% on 2026-05-06
$5.85▲ +29.71%
over 1Y
L $4.19EODHDH $9.56
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today—
1W+0.9%
1M-5.9%
3M-17.8%
YTD-29.1%
1Y+29.7%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Buy
Revenue grew 8.7% YoY; but unprofitable (net margin -102.0%).
Vanda Pharmaceuticals Inc. shows $216M in FY2025 revenue (+8.7% YoY), a -102.0% net margin, and -67.4% ROE.
Sources: SEC EDGAR (CIK 0001347178, latest 10-Q filed 2026-05-07) · as of 6/26/2026, 6:34:30 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.